Gastric Cancer Treatment Market, By Treatment (Surgery, Chemo Therapy, Adjuvant Chemotherapy, Targeted Drugs Therapy (Sunitinib (Sutent), Trastuzumab (Herceptin), and Imatinib (Gleevec)), and Radiation Therapy), By End-User (Hospitals, Clinics, Specialized Cancer Treatment Centers, and Ambulatory Surgical Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa - Trends, Analysis and Forecast till 2034

An increase in government healthcare spending

Global government spending on healthcare has increased significantly in recent years, which may accelerate the expansion of the gastric cancer treatment market- establishing new R&D facilities to aid in the progress of current technologies and launching a novel treatment approach that will ultimately lead to the growth of the target market. Increasing the variety of attributes of medical infrastructure also aids in the early detection or diagnosis of stomach cancer. 

For example, the National Cancer Institute reports that, in F.Y. (Fiscal Year) 2023, the U.S. Congress provided NCI with a budget of $7.3 billion as part of the federal budget process through appropriations for the NIH and the Department of Health and Human Services. The spending plan was $216 million, which went toward the NCI portion of the Cancer Moonshot, part of a $408 million increase over the level established for F.Y. 2022.